Initial Single-Center Experience With Levosimendan Infusion for Perioperative Management of Univentricular Heart With Ductal-Dependent Systemic Circulation

Cristiana Garisto, Isabella Favia, Zaccaria Ricci, Luca di Chiara, Stefano Morelli, Chiara Giorni, Vincenzo Vitale, Sergio Picardo, Roberto M. di Donato

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The aim of this study was to evaluate the safety and the efficacy of levosimendan, a novel calcium sensitizer agent, on postoperative hemodynamic and metabolic parameters of neonates affected by single ventricle anatomy. Twenty consecutive neonates scheduled for the Norwood procedure with Blalock Taussig shunt were prospectively enrolled. All patients received an infusion of levosimendan at 0.1 μg/kg/min commencing 24 hours before surgery, and the infusion was continued for 48 hours after surgery. No side effects (intolerance to the drug, hypotension, arrhythmias) were shown. A median inotropic score (IS) of 37 was necessary to maintain a mean arterial pressure between 45 and 50 mm Hg at intensive care unit (ICU) admission: IS was significantly reduced after 72 hours (P < .05). Brain natriuretic peptide values decreased significantly from 1210 to 459 pg/mL in 72 hours (P < .05). Median SvO2 increased significantly from 38% to 59% during the evaluated period (P < .05). Cerebral near-infrared spectroscopy values were close to 40% at ICU admission with a significant stable increase to 50% after 12 hours (P < .05). Median lactate level was 13 mmol/L at ICU admission but showed a trend to a rapid and significant decrease after 12 hours (P < .05). Median urine output was surprisingly elevated, always remaining between 5.2 and 6.2 mL/kg/h throughout the postoperative period. Survival rate was 85% at 30 days (17/20 patients) and 75% (15/20) at hospital discharge. Levosimendan infusion in a cohort of neonates with univentricular anatomy was safe and potentially beneficial on postoperative hemodynamic and metabolic parameters.

Original languageEnglish
Pages (from-to)292-299
Number of pages8
JournalWorld Journal for Pediatric and Congenital Hearth Surgery
Volume1
Issue number3
DOIs
Publication statusPublished - 2010

Fingerprint

Intensive Care Units
Newborn Infant
Anatomy
Norwood Procedures
Hemodynamics
Blalock-Taussig Procedure
Near-Infrared Spectroscopy
Brain Natriuretic Peptide
Postoperative Period
Hypotension
Cardiac Arrhythmias
Lactic Acid
Arterial Pressure
Survival Rate
Urine
Calcium
Safety
Pharmaceutical Preparations
simendan

Keywords

  • inotropic score
  • levosimendan
  • pediatric cardiac surgery
  • univentricular heart

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Cite this

@article{b3882835bf4b4342bd1a79eaf4277d49,
title = "Initial Single-Center Experience With Levosimendan Infusion for Perioperative Management of Univentricular Heart With Ductal-Dependent Systemic Circulation",
abstract = "The aim of this study was to evaluate the safety and the efficacy of levosimendan, a novel calcium sensitizer agent, on postoperative hemodynamic and metabolic parameters of neonates affected by single ventricle anatomy. Twenty consecutive neonates scheduled for the Norwood procedure with Blalock Taussig shunt were prospectively enrolled. All patients received an infusion of levosimendan at 0.1 μg/kg/min commencing 24 hours before surgery, and the infusion was continued for 48 hours after surgery. No side effects (intolerance to the drug, hypotension, arrhythmias) were shown. A median inotropic score (IS) of 37 was necessary to maintain a mean arterial pressure between 45 and 50 mm Hg at intensive care unit (ICU) admission: IS was significantly reduced after 72 hours (P < .05). Brain natriuretic peptide values decreased significantly from 1210 to 459 pg/mL in 72 hours (P < .05). Median SvO2 increased significantly from 38{\%} to 59{\%} during the evaluated period (P < .05). Cerebral near-infrared spectroscopy values were close to 40{\%} at ICU admission with a significant stable increase to 50{\%} after 12 hours (P < .05). Median lactate level was 13 mmol/L at ICU admission but showed a trend to a rapid and significant decrease after 12 hours (P < .05). Median urine output was surprisingly elevated, always remaining between 5.2 and 6.2 mL/kg/h throughout the postoperative period. Survival rate was 85{\%} at 30 days (17/20 patients) and 75{\%} (15/20) at hospital discharge. Levosimendan infusion in a cohort of neonates with univentricular anatomy was safe and potentially beneficial on postoperative hemodynamic and metabolic parameters.",
keywords = "inotropic score, levosimendan, pediatric cardiac surgery, univentricular heart",
author = "Cristiana Garisto and Isabella Favia and Zaccaria Ricci and Chiara, {Luca di} and Stefano Morelli and Chiara Giorni and Vincenzo Vitale and Sergio Picardo and {di Donato}, {Roberto M.}",
year = "2010",
doi = "10.1177/2150135110378310",
language = "English",
volume = "1",
pages = "292--299",
journal = "World journal for pediatric & congenital heart surgery",
issn = "2150-1351",
publisher = "Sage Periodicals Press",
number = "3",

}

TY - JOUR

T1 - Initial Single-Center Experience With Levosimendan Infusion for Perioperative Management of Univentricular Heart With Ductal-Dependent Systemic Circulation

AU - Garisto, Cristiana

AU - Favia, Isabella

AU - Ricci, Zaccaria

AU - Chiara, Luca di

AU - Morelli, Stefano

AU - Giorni, Chiara

AU - Vitale, Vincenzo

AU - Picardo, Sergio

AU - di Donato, Roberto M.

PY - 2010

Y1 - 2010

N2 - The aim of this study was to evaluate the safety and the efficacy of levosimendan, a novel calcium sensitizer agent, on postoperative hemodynamic and metabolic parameters of neonates affected by single ventricle anatomy. Twenty consecutive neonates scheduled for the Norwood procedure with Blalock Taussig shunt were prospectively enrolled. All patients received an infusion of levosimendan at 0.1 μg/kg/min commencing 24 hours before surgery, and the infusion was continued for 48 hours after surgery. No side effects (intolerance to the drug, hypotension, arrhythmias) were shown. A median inotropic score (IS) of 37 was necessary to maintain a mean arterial pressure between 45 and 50 mm Hg at intensive care unit (ICU) admission: IS was significantly reduced after 72 hours (P < .05). Brain natriuretic peptide values decreased significantly from 1210 to 459 pg/mL in 72 hours (P < .05). Median SvO2 increased significantly from 38% to 59% during the evaluated period (P < .05). Cerebral near-infrared spectroscopy values were close to 40% at ICU admission with a significant stable increase to 50% after 12 hours (P < .05). Median lactate level was 13 mmol/L at ICU admission but showed a trend to a rapid and significant decrease after 12 hours (P < .05). Median urine output was surprisingly elevated, always remaining between 5.2 and 6.2 mL/kg/h throughout the postoperative period. Survival rate was 85% at 30 days (17/20 patients) and 75% (15/20) at hospital discharge. Levosimendan infusion in a cohort of neonates with univentricular anatomy was safe and potentially beneficial on postoperative hemodynamic and metabolic parameters.

AB - The aim of this study was to evaluate the safety and the efficacy of levosimendan, a novel calcium sensitizer agent, on postoperative hemodynamic and metabolic parameters of neonates affected by single ventricle anatomy. Twenty consecutive neonates scheduled for the Norwood procedure with Blalock Taussig shunt were prospectively enrolled. All patients received an infusion of levosimendan at 0.1 μg/kg/min commencing 24 hours before surgery, and the infusion was continued for 48 hours after surgery. No side effects (intolerance to the drug, hypotension, arrhythmias) were shown. A median inotropic score (IS) of 37 was necessary to maintain a mean arterial pressure between 45 and 50 mm Hg at intensive care unit (ICU) admission: IS was significantly reduced after 72 hours (P < .05). Brain natriuretic peptide values decreased significantly from 1210 to 459 pg/mL in 72 hours (P < .05). Median SvO2 increased significantly from 38% to 59% during the evaluated period (P < .05). Cerebral near-infrared spectroscopy values were close to 40% at ICU admission with a significant stable increase to 50% after 12 hours (P < .05). Median lactate level was 13 mmol/L at ICU admission but showed a trend to a rapid and significant decrease after 12 hours (P < .05). Median urine output was surprisingly elevated, always remaining between 5.2 and 6.2 mL/kg/h throughout the postoperative period. Survival rate was 85% at 30 days (17/20 patients) and 75% (15/20) at hospital discharge. Levosimendan infusion in a cohort of neonates with univentricular anatomy was safe and potentially beneficial on postoperative hemodynamic and metabolic parameters.

KW - inotropic score

KW - levosimendan

KW - pediatric cardiac surgery

KW - univentricular heart

UR - http://www.scopus.com/inward/record.url?scp=84990347713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990347713&partnerID=8YFLogxK

U2 - 10.1177/2150135110378310

DO - 10.1177/2150135110378310

M3 - Article

AN - SCOPUS:84990347713

VL - 1

SP - 292

EP - 299

JO - World journal for pediatric & congenital heart surgery

JF - World journal for pediatric & congenital heart surgery

SN - 2150-1351

IS - 3

ER -